Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Houston Methodist Research Institute currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to a distinct art unit, reflecting a highly concentrated prosecution focus. The presence of only 1 distinct examiner suggests that the institute's current interactions with the patent office are limited to a specific technical niche within the life sciences. This concentration allows the applicant to focus all resources on a single set of examiner concerns.
OGUNBIYI, OLUWATOSIN A is identified as the busiest examiner, currently overseeing the pending office action. This individual accounts for the entirety of the institute's pending workload at this time. For practitioners, this means that the immediate success of the portfolio's prosecution depends entirely on the dialogue with this specific examiner and the standards of the single art unit involved. There are no other active matters to create conflicting priorities or require different technical arguments.
Given that there is only a single pending office action, the portfolio does not currently face the complexities of managing conflicting examiner requirements across multiple applications. The focus remains on a singular point of contact within the Biotechnology & Pharmaceuticals sector, allowing for a streamlined response strategy tailored to the expectations of OGUNBIYI, OLUWATOSIN A. This focused approach is typical for portfolios with limited active filings, where the goal is to resolve the outstanding matter efficiently. Success in the distinct art unit will be the primary indicator of the institute's current patenting progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550036 | NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Final Rejection | 17d overdue | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial